ClinVar Miner

Submissions for variant NM_000138.5(FBN1):c.6007G>A (p.Gly2003Arg)

gnomAD frequency: 0.00002  dbSNP: rs1413737899
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001002237 SCV001160112 uncertain significance not specified 2018-11-15 criteria provided, single submitter clinical testing The FBN1 c.6007G>A; p.Gly2003Arg variant is reported in the literature in at least one individual affected with severe adolescent idiopathic scoliosis (Buchan 2014). This variant is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. The glycine at codon 2003 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Other computational analyses (Alamut v.2.11) predict that this variant may impact splicing by creating a novel cryptic acceptor splice site, but the effects on splicing are unknown. Due to limited information, the clinical significance of the p.Gly2003Arg variant is uncertain at this time. References: Buchan JG et al. Rare variants in FBN1 and FBN2 are associated with severe adolescent idiopathic scoliosis. Hum Mol Genet. 2014 Oct 1;23(19):5271-82.
Color Diagnostics, LLC DBA Color Health RCV001190656 SCV001358209 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2022-12-12 criteria provided, single submitter clinical testing This missense variant replaces glycine with arginine at codon 2003 of the FBN1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools are inconclusive regarding the impact of this variant on RNA splicing. A functional study has shown that the mutant protein perturbs TGF-Beta signaling pathway (PMID: 31774634). This variant has been reported in an individual affected with adolescent idiopathic scoliosis (PMID: 24833718, 26333736). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Invitae RCV001316848 SCV001507487 uncertain significance Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection 2022-08-27 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 2003 of the FBN1 protein (p.Gly2003Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with adolescent idiopathic scoliosis (PMID: 24833718). ClinVar contains an entry for this variant (Variation ID: 811830). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function. Experimental studies have shown that this missense change affects FBN1 function (PMID: 31774634). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Institute of Human Genetics, University Hospital Muenster RCV002287456 SCV002577789 uncertain significance See cases 2021-12-08 criteria provided, single submitter clinical testing ACMG categories: PM2,PP3,BP1
Fulgent Genetics, Fulgent Genetics RCV002479194 SCV002790518 uncertain significance Ectopia lentis 1, isolated, autosomal dominant; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill-Marchesani syndrome 2, dominant; Acromicric dysplasia; Geleophysic dysplasia 2; Progeroid and marfanoid aspect-lipodystrophy syndrome 2021-11-10 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV004004471 SCV004814612 uncertain significance Marfan syndrome 2023-10-30 criteria provided, single submitter clinical testing This missense variant replaces glycine with arginine at codon 2003 of the FBN1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools are inconclusive regarding the impact of this variant on RNA splicing. A functional study has shown that the mutant protein perturbs TGF-beta- signaling pathway (PMID: 31774634). This variant has been reported in an individual affected with adolescent idiopathic scoliosis (PMID: 24833718, 26333736). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Ambry Genetics RCV001190656 SCV005032433 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2024-02-09 criteria provided, single submitter clinical testing The p.G2003R variant (also known as c.6007G>A), located in coding exon 48 of the FBN1 gene, results from a G to A substitution at nucleotide position 6007. The glycine at codon 2003 is replaced by arginine, an amino acid with dissimilar properties. This alteration was reported in an adolescent idiopathic scoliosis cohort (Buchan JG et al. Hum Mol Genet, 2014 Oct;23:5271-82). This alteration may have an impact on protein function (Lin M et al. Mol Genet Genomic Med, 2020 Jan;8:e1023). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear.
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV001724206 SCV001957353 likely pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV001724206 SCV001973976 likely pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.